Indicated for: prevention and treatment of thromboembolism
Route of administration: oral
Substance: dabigatran etexilat (anticoagulant)
ATC: B01AE07 (Blood and blood forming organs | Antithrombotic agents | Direct thrombin inhibitors)
Dabigatran etexilate is an oral anticoagulant used for the prevention and treatment of blood clots. It is indicated for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation, as well as for the treatment and prevention of deep vein thrombosis (DVT) and pulmonary embolism (PE).
Dabigatran etexilate works as a direct thrombin inhibitor, preventing the formation of blood clots. It is administered orally in capsule form, with the dosage adjusted based on the patient's condition and bleeding risk.
Side effects may include bleeding (nasal, gastrointestinal, or other types), dyspepsia (heartburn), nausea, or allergic reactions. It is contraindicated in patients with active bleeding, severe renal impairment, or hypersensitivity to the substance. It should also be used cautiously in patients with a high risk of bleeding.
Price
Copayment
Patient
195.25 RON
97.62 RON
97.63 RON